10x Genomics, Inc. is maintaining its full year 2022 revenue guidance of $600 million to $630 million, representing 22% to 28% growth over full year 2021 revenue.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.77 USD | +2.39% | -0.92% | -32.72% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.72% | 4.4B | |
-4.69% | 8.1B | |
-3.65% | 5.13B | |
+2.96% | 4.72B | |
-0.97% | 4.14B | |
+15.50% | 2.82B | |
+3.24% | 2.55B | |
+12.70% | 1.92B | |
-1.77% | 1.65B | |
-2.09% | 1.52B |
- Stock
- Equities
- Stock 10x Genomics, Inc. - Nasdaq
- News 10x Genomics, Inc.
- 10x Genomics, Inc. Maintains Revenue Guidance for Full Year 2022